

Scotland's Rural College

Strategies for screening young stock for antibodies - optimising numbers to test, cut-points & predictive values for bovine viral diarrhoea virus

Humphry, RW; Reeves, A; Gunn, GJ

Published in:
Scientific Reports

DOI:
[10.1038/s41598-018-27870-8](https://doi.org/10.1038/s41598-018-27870-8)

First published: 22/06/2018

Document Version
Peer reviewed version

[Link to publication](#)

Citation for pulished version (APA):

Humphry, RW., Reeves, A., & Gunn, GJ. (2018). Strategies for screening young stock for antibodies - optimising numbers to test, cut-points & predictive values for bovine viral diarrhoea virus. *Scientific Reports*, 8(1), [9532]. <https://doi.org/10.1038/s41598-018-27870-8>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

- 1 **Original Article for submission to Scientific Reports**
- 2 **Strategies for screening young stock for antibodies – optimising numbers to test, cut-points, &**
- 3 **predictive values for bovine viral diarrhoea virus.**
- 4 Humphry*, R.W., Reeves, A., & Gunn G.J.
- 5 Epidemiology Research Unit, (Inverness campus), Scotland’s Rural College (SRUC), Kings Buildings,
- 6 West Mains Road, Edinburgh, EH9 3JG, U.K.
- 7 *Corresponding author. +44 1463 246059
- 8 E-mail address: roger.humphry@sruc.ac.uk (R. W. Humphry)
- 9

10 Abstract (<=200 words)

11 The antibody seroprevalence of young stock can be a useful indicator of recent or current infection
12 in a herd. We examine the factors that contribute to the assessment of herd exposure to disease, via
13 spot testing for antibody, using bovine viral diarrhoea virus (BVDv) as an example.

14 A statistical distribution of seroprevalences for BVDv in beef herds identified three groups of herds:
15 low, intermediate and high within-herd BVDv antibody seroprevalence. We tested two assumptions
16 –the intermediate seroprevalence group of herds is assumed to be negative for BVDv at the herd
17 level and alternatively if this group is assumed to be positive.

18 We found that:

19 The herd-level sensitivity and specificity are sensitive to the assumption regarding the herds with
20 intermediate seroprevalence

21 If an appropriate cut-point is chosen, reducing the sample size from ten to five does not produce
22 a large drop in herd-level test performance

23 Increasing the cut-point may be valuable at the outset of an eradication programme

24 Increasing the sample size and decreasing the cut-point is advantageous towards the end of an
25 eradication programme, to minimise the risk of positive herds being misclassified

26 The framework presented here illustrates how seroprevalence screening may be understood and
27 assessed.

28 *Keywords:* sample size; cut-point; seroprevalence; BVDv; herd-level test sensitivity and specificity

29

30 Introduction

31 For most infectious agents, antibodies measured in animals by an ELISA test provide information
32 about the recent or historic exposure of those animals to the infectious agent. The prevalence of
33 animals with high antibody levels (*i.e.*, antibody seroprevalence) may thus be used to identify herds
34 that have been recently or currently are being exposed to the infectious agent. This principle has
35 been employed in the screening of herds for infectious diseases, such as bovine viral diarrhoea virus
36 (BVDv) in cattle.

37 BVDv is the infectious agent of a serious cattle disease of economic importance ^{1,2}. BVDv is amenable
38 to eradication at a national level if suitable testing and management in response to testing are put
39 into action ^{3,4}. It is possible to test directly for antigen to BVDv amongst individual animals but, if
40 missed, an infectious animal can cause serious break down in status for the herd and result in
41 further cycles of infection. An alternative method of identifying BVDv-infected herds involves the
42 screening of animals for antibodies and the use of screening results as an indicator of virus
43 circulating in the herd. For this primary screen based on antibodies it is common to screen young
44 stock since their antibody levels are indicative of recent infection and it is the recent status of the
45 herd which is typically of most interest ⁵. If a herd is deemed to be BVDv-positive (*i.e.*, infected) on
46 the basis of the detection of antibody-positive animals, a subsequent and more extensive search for
47 antigen-positive (and potentially infectious) animals within the herd typically will be conducted. A
48 particular aim of such subsequent screening is the identification of persistently infected ("PI")
49 animals, which are epidemiologically important for the continued spread of disease ^{6,7}.

50 Using the presence of antibody-positive animals to identify infected herds is dependent upon several
51 factors. Levels of within-herd antibody seroprevalence have been found to vary across populations
52 of herds ^{5,8}. The variation in seroprevalence amongst herds that are truly BVDv-positive as well as
53 among those that are truly BVDv-negative (*i.e.* not infected) will impact the results of a screening
54 test. Among the other factors that will affect the performance of a screening test are the following:

- 55 • The sensitivity and specificity of the antibody test at the level of the individual animal;
- 56 • The number of animals to be tested or sampled; and
- 57 • The use of an appropriate cut-point or threshold for the number of test-positive animals in
- 58 the sample at which the herd (or flock) is deemed positive.

59 Together, these factors contribute to the specificity and sensitivity of the screening test at the level
60 of the whole herd.

61 Screening programmes for BVDv which utilise testing for antibodies in individual sera from young
62 stock vary in the number of animals they require to be tested and in the cut-point , *i.e.*, the number
63 of seropositive animals which must be detected in the sample in order for the herd to be deemed
64 positive. For example, the first mandatory testing stage of the Scottish eradication scheme ⁹ required
65 five or ten young animals to be tested per management group depending on the age of the young
66 stock with an implicit cut-point of one positive animal albeit with scope for reinterpretation by the
67 veterinarian in the case of low numbers of animals with low or inconclusive antibody levels¹⁰.

68

69 Thus the detection of even a single antibody seropositive animal in the sample was sufficient for the
70 herd to be deemed positive for BVDv. In the eradication programme proposed for the Netherlands
71 an initial screening of five young stock leads to additional testing if two or more tested animals are
72 found to be antibody positive (Pers. Comm. Duijn, L. van 8/6/17).

73 .

74 As noted above, the within-herd BVDv antibody seroprevalence varies among herds. The statistical
75 distribution of seroprevalence amongst young stock is generally U-shaped with a large proportion of
76 herds with zero or close to zero seroprevalence and a large proportion with close to 100%
77 seroprevalence ⁵. However, there is also evidence of a middle group or class of herds with
78 intermediate seroprevalence (Figure 1) ^{8,11,12}. It is not clear whether herds in this group are truly

79 BVDv-positive, BVDv-negative or a mix of both. How herds in this middle group are considered has
80 implications for BVDv screening. In this paper we estimate the herd-level sensitivity and specificity of
81 screening tests under various conditions, considering the range of within-herd BVDv antibody
82 seroprevalence levels, different numbers of animals tested and different cut-points for the threshold
83 above which a herd is deemed positive. Our objective is to provide quantitative evidence for those
84 designing schemes of the herd-level test performance of young stock screening for BVDv. An
85 additional objective is to provide policy implications that vary between the outset of an eradication
86 scheme (when herd-level prevalence is high) and the latter stages of an eradication scheme (when
87 false negatives are costly to the eradication scheme). We also consider the importance of the
88 middle group and how it may affect the interpretation of the results of screening for antibodies in
89 young stock.

90

91

92 Results

93 Results of test performance at the herd-level are presented for the following combination of
94 scenarios (Figure 2):

- 95 • Treatment of herds with intermediate levels of antibody seroprevalence as either BVDv
96 negative or positive;
- 97 • Testing of five or ten animals; and
- 98 • Use of a cut-point or threshold (i.e. the number of positive animals at, or above which, the
99 herd is declared positive) of different numbers of animals.

100 From results illustrated in Figure 2, we note that the herd-level sensitivity drops and the herd-level
101 specificity increases as the cut-point number of animals increases. It is also clear that the sensitivity
102 is much higher and specificity lower if the group of herds with intermediate seroprevalence in the
103 original distribution is considered negative rather than positive. The designation of the group of
104 herds with intermediate levels of seroprevalence is very important in deciding the optimum cut-
105 point. If this group is considered positive, then with a sample size of ten the optimum cut-point
106 arguably is two positive animals. By contrast, if this group is considered negative, then the optimum
107 cut-point is arguably six to achieve both high sensitivity and specificity. There is a similar pattern
108 when considering a sample size of five animals. The optimum cut-point appears to be one positive in
109 the case of the middle component being positive and three positives from a sample of five in the
110 case of the middle component being negative.

111 Table 1 provides the herd-level performance estimates for a testing regime within a recommended
112 control programme. Table 2 provides the overall probability of a false negative, the overall
113 probability of a false positive, positive predictive value and negative predictive value under the
114 eradication scheme in the Netherlands plus the consequences of reducing the cut-point r of
115 seropositive animals from two to one.

116 The “false negative rate” is the probability that a truly positive herd tests negative (that is, the
117 numerator is the number of truly positive herds which test negative, and the denominator is the
118 number of truly positive herds) ¹³. Possibly of greater interest to the policy maker is the probability
119 that *any* herd randomly selected from a population of herds is truly positive *and* tests negative (the
120 numerator is unchanged, but the denominator in this case is the total number of herds). Here we
121 use the term “overall probability of a false negative” to distinguish this value from the false negative
122 rate. The overall probability of a false negative is simply the true herd-level prevalence multiplied by
123 the false negative rate.

124 The overall probability of a false negative naturally increases linearly with herd-level prevalence
125 (Figures 3 & 4). It is noticeable that by dropping the cut-point from two (Figure 3) to one (Figure 5,
126 Table 2) the overall probability of a false negative is decreased substantially. For a given cut-point,
127 increasing the number of animals tested lowers the overall probability of a false negative (Figures 2,
128 3 & 4).

We illustrate the consequences of our assumption for the status of the intermediate seroprevalence group for a scenario provided within the Dutch eradication scheme in which the number of animals tested is five and the cut-point is two (Table 1). This demonstrates how much the sensitivity and specificity of the test depends on this assumption with the sensitivity changing from 75% to 100% under the two assumptions.

In Table 2 we present the overall probability of false negatives and false positives. False negatives in particular are undesirable towards the latter stages of eradication when most herds and most animals are susceptible and therefore at risk of infection through the failure to identify a positive herd. We see that even though the overall probability of a false negative is lower when the prevalence is lower, the overall probability of a false negative can be reduced further by lowering the cut-point to one.

In Figures 3 and 4 we see the linear relationship between the herd level prevalence and the overall median probability of false negatives. We see that as the number of animals tested goes up for a fixed cut-point the overall probability of a false negative goes down. Finally we note that for any particular number of animals tested, if the cut point is reduced to one then the overall probability of a false negative decreases.

We do not present figures for the median overall probability of false negatives when herds with intermediate within-herd seroprevalence are treated as negative because in that situation the median rate of false negatives is zero for both a cut-point of one or two positive animals.

151 Discussion

152 For most infectious agents, antibodies measured in animals by an ELISA test provide information
153 about the recent or historic exposure of those animals to the infectious agent. The prevalence of
154 animals with high antibody levels (i.e., seroprevalence) may thus be used to identify herds that have
155 been or are being exposed to high levels of the infectious agent, provided that estimates of
156 seroprevalence can be interpreted as a herd-level result. In this study we employ the example of
157 BVDv to demonstrate how the herd-level sensitivity and specificity might be estimated on the basis
158 of an interpretation of seroprevalence data collected from young stock in Scottish beef suckler
159 herds.

160 *Relevant epidemiological attributes of BVDv*

161 A natural gold standard for defining a herd as BVDv positive is evidence of circulating virus in the
162 herd and therefore evidence of the presence of at least one persistently or transiently infected
163 animal in the herd, which might be detected on the basis of screening animals for virus or for BVDv
164 antigens. Such screening would require a great deal of testing (of every or nearly every animal in a
165 herd), and the consequences of a false negative result could be substantial. Alternatively, however,
166 the epidemiology of BVD virus is such that the presence of BVD virus in the herd is amenable to
167 screening by testing for antibodies in animals of any age, and particularly in young stock. A study¹⁴
168 found that the within-herd antibody seroprevalence from herds in which an antigen-positive animal
169 was identified was 87% whilst it was only 43% in herds in which no antigen-positive animal was
170 found. Therefore the within-herd prevalence of antibody-positive animals may be effectively used as
171 a proxy or indicator for the presence or absence of antigen-positive animals.

172 *Optimising the number of animals to test and the cut-point value*

173 When a number of individual animals are tested for antibody in order to determine a binary (i.e.,
174 positive or negative) herd status, there are two important decisions to be made. The first is the

number of animals to be tested and the second is the cut-point for the number of positive animals at or above which the herd is deemed positive. Commonly the number of animals to be tested in BVDv eradication programmes is 5-10 young stock^{5,9,15-17} although it has been suggested that as few as three young stock might need testing¹⁷ especially if the antibody test is done in tandem with antigen testing¹⁸. A BVDv eradication programme now being initiated in the Netherlands involves initial antibody spot-testing of five animals, with a cut-point for the number of antibody-positive animals of two. One clear benefit of choosing a cut-point of two (as opposed to one) is that it reduces the risk of false positives and thus reduces the risk of unnecessary and expensive secondary testing of the whole herd. Our work informs decisions regarding sample numbers and threshold values under different conditions.

The optimum threshold number, or cut-point, of antibody-positive animals for making a herd-level determination is dependent on the number of animals sampled. If ten animals are tested then the optimum cut-point appears to be greater than one (Figure 2). This matches recommendations published elsewhere^{5,19}. In our analysis the optimum appears to be two positive animals out of ten, if the intermediate seroprevalence group is considered positive and a cut-point of around seven positive animals if the intermediate seroprevalence group is considered to be negative (Figure 2). Whilst it appears justified from an epidemiological point of view, using a cut-point of greater than one may be counter-intuitive to farmers and veterinary practitioners. To use a cut-point of greater than one is to lose some sensitivity of the test but to gain specificity i.e. to reduce the probability of false positives. As discussed below, the best balance between sensitivity and specificity is dependent upon the stage of a disease eradication programme, as discussed below.

Performance of the individual level test

Our approach to estimating the *group*-level sensitivity and specificity is based on within-herd prevalence of antibody-positive animals, however it is worth noting that the *individual* tests are not perfect either. In the survey on which our simulations are based, the test used was Svanovir BVDV

antibody ELISA²⁰. This test is reported (by the manufacturer) to have a sensitivity and specificity of 100% and 98.2% respectively in comparison to a virus neutralisation test. In our simulations we have used the sensitivity and specificity from the statistical distributions reported in the study⁸ on which our simulations are based. The sensitivity (and 95% confidence interval) is 96.3% (91.9%, 99.8%) and the specificity is 98.8% (98.0%, 99.3%).

Our study is based on the categorisation of individual antibody scores into a binary positive or negative result by comparing the antibody scores with a cut-off. This is the conventional way of interpreting individual antibody results and is both convenient and easily interpreted. However, when we scale up to testing at the group level it is possible that the loss of information that is involved in categorising a continuous antibody score into a binary positive or negative is an important loss of information. For example, it is possible that having several calves with an antibody score just below the cut-off is a better predictor of a positive herd than having only one calf just above the cut-off. Current eradication schemes tend not to be set up to report individual antibody scores, and it is not known how frequently such a situation might occur. To take into account the individual antibody scores would require further investigation, ideally using data pertaining to individual antibody scores from sampled calves from herds with and without PI animals. The interpretation would require a multivariate analysis to optimally interpret several antibody scores without recourse to the binary categorisation. Such an approach might improve the herd-level test performance but might be unattractive to veterinary practitioners and to producers because it would involve complex and non-transparent calculations.

The effect of herds characterised by intermediate within-herd antibody seroprevalence levels

The extent to which antibody seroprevalence can be used to determine herd-level status of infection is dependent on the level of separation of the frequency distribution of seroprevalence values in

negative herds compared to the distribution in positive herds (see Figure 1). The greater the separation of these frequency distributions, the easier it is to observe separate groups or classes of herds (aka “components” in the statistical literature) within the overall distribution. Various statistical methods exist for identifying and describing such classes or groups in a frequency distribution. The results we present here are predicated on the empirical description of such classes from a randomised study of Scottish beef herds prior to the Scottish eradication scheme⁸. The Scottish study found three classes, characterised by low, intermediate and high seroprevalence. Our analyses are based on the assumption that those groups represent different epidemiological herd statuses. The analyses are made complex by the fact that the epidemiological status of the group of herds characterised by intermediate levels of antibody seroprevalence is uncertain. Ideally we would have data from the same herds on both the within-herd seroprevalence for young stock and whether or not an infected animal exists in the herd. With such data we would be able to confidently describe the status of herds in the group with intermediate seroprevalence, but in the absence of such data we can consider the two extremes – i.e. that all herds in this group are either negative or positive. It is probable that this group of herds with intermediate seroprevalence consist of a mixture of truly positive and truly negative herds, in which case the correct interpretation would lie between the two extremes presented here.

It is worth considering the wider evidence regarding the existence of a group of herds with intermediate seroprevalence levels. Other studies have presented data suggesting the possible existence of such a group^{11,12}. On the other hand at least one study exists in which there was no obvious middle component in the distribution of within-herd seroprevalence⁵.

There are various possible causes of intermediate seroprevalence in some herds:

- Existence of residual maternal antibody derived from dams in young stock that have not, in fact, been exposed to the virus
- The young stock have been vaccinated

- The young stock were exposed to low levels of virus (for example, over fence from a PI or transiently infected animal) leading to a low antibody response
- Fomite contamination – leading to low antibody response and hence low prevalence
- Exposure to a particular strain of virus that causes low antibody response
- Heterogeneity in ages of the sampling group – if there are some new recruits to the group post-exposure they will be antibody negative and will “dilute” the group and hence reduce the prevalence

In our analyses we have combined the intermediate seroprevalence group with either the low seroprevalence (negative) group or the high seroprevalence (positive) group. In doing so, we have effectively created a mixture of two, rather than three, groups. The resulting mixture depends upon the relative proportional contribution each group gives and we have, implicitly, used the relative proportions outlined in the original description of the three groups (Figure 1). It is likely the contribution that the intermediate seroprevalence group makes to the overall distribution is not constant across time or between countries. It is not clear, however, whether we can predict how its contribution will vary. For example, in the case of a country or region with an eradication scheme such as that in Scotland, it is possible to envisage either an increase or decrease in the proportion of herds that fall into the intermediate seroprevalence category. During an eradication scheme, if all goes well, there is “movement” of herds from the right hand end of the seroprevalence frequency distribution (Figure 1) towards the left hand end of the distribution. Therefore it is not possible to predict whether the middle group will gain more from the high seroprevalence group than it loses to the low seroprevalence group.

Consequences of misunderstanding the status of the intermediate seroprevalence group

The large differences in herd-level test characteristics such as sensitivity, specificity, false negative and false positive rates, depending on whether the intermediate seroprevalence group is assumed to be negative or positive (Figures 2, 3, 4; Tables 1 & 2) highlight the importance of better

understanding this group's epidemiological status if we wish to improve the accuracy of our estimates of these test characteristics. For example, in Figure 2, it appears that, for a sample size of ten young stock, the trade-off between herd-level sensitivity and specificity is optimal with a cut-point of two if the middle component is positive but it is a cut-point of six or seven if the middle component is negative. Therefore the consequence of misunderstanding the status of the intermediate seroprevalence group is large – and in particular may lead to poor selection of the number of animals to test and poor selection of cut-points.

It is also worth noting that whatever the true status of intermediate seroprevalence group, the assumption that it represents truly positive herds results in estimates of the herd-level sensitivity which are lower than, or equal to, the actual herd-level sensitivity: this then represents a “worse case” estimate of herd-level sensitivity. It is therefore a “conservative” estimate for herd-level sensitivity. If this group were composed either partly or wholly of truly negative herds, then the actual herd-level sensitivity would be higher than predicted on the basis of the assumption that they are all truly positive. The opposite relationship can be seen for herd-level specificity: assuming that the intermediate seroprevalence group is positive results in estimates for this parameter which might be higher than the actual value. Whether it is preferable to under-estimate herd-level sensitivity or specificity of a test may be dependent on other conditions, as discussed below. Which of these test characteristics (sensitivity or specificity) is more important may determine which assumption, regarding the intermediate prevalence group, is the more “conservative” or risk-averse at a particular time.

The final stages of an eradication scheme

We may also consider the relative importance of herd-level sensitivity and specificity towards the end of an eradication scheme when the prevalence is low compared to the early stages of an eradication scheme when the prevalence is high. In these latter stages of an eradication scheme it becomes more important that positive herds are accurately identified than it is in the early stages

when it is typically accepted (and is less consequential) that some positive herds may be incorrectly classified as negative. This is because as the population approaches total susceptibility, the epidemiological, economic and political consequences of reintroduction become substantial⁶. Therefore it is important that the test sensitivity is particularly high during the final stages of eradication even if this comes with the increased risk of false positives. To achieve a meaningful and maximum sensitivity indicates a cut-point of just one antibody positive animal. Thus the overall probability of a false negative is reduced if the number of animals tested is increased to ten and the cut-point is held at one (Figures 2, 3). The consequent high risk of false positives due to the low specificity (Figure 2 and Table 2) will require diplomatic explanations to farmers and veterinary practitioners. Specifically the explanation needed is that an initial positive result requires subsequent testing before the result is accepted as genuinely positive. Typically this subsequent test could be a full herd antigen screening for PI animals. Such a two-stage process in response to an initial positive result is a reasonable way of screening a herd before declaring its status. The proposed scheme in the Netherlands is based on follow up tests if the number of positive animals is equal to or higher than the cut-point (which is two out of five young stock in this example).

315 Conclusions

316 In conclusion, we find that:

- 317 • The true status of the intermediate seroprevalence group is crucial, and analyses of herd-
318 level sensitivity and specificity are highly dependent on the assumed status of this group.
319 Misunderstanding the true status of this group will lead to imperfect design of a screening
320 scheme and in particular poor selection of cut-points;
- 321 • Reducing the number of young stock screened for BVDv antibody from ten to five need not
322 result in a substantial drop in herd-level sensitivity and specificity if the appropriate cut-
323 point is selected;
- 324 • Increasing the cut-point to a value greater than one for the number of antibody seropositive
325 animals before treating a herd as positive may be useful at the outset of an eradication
326 scheme; The benefit of doing so is to increase the specificity, and reduce the cost of
327 unnecessary secondary whole herd screening that is associated with a false positive.
- 328 • Increasing the number of animals tested, reducing the cut-point to one, or adopting both
329 actions in the latter stages of an eradication scheme is warranted in order to maximise the
330 herd-level sensitivity and thus reduce the number of false negative herds to as great an
331 extent possible.

332 We believe this paper provides a useful example of a framework for understanding the complexity of
333 measuring herd exposure to an infectious agent using a spot-test approach. It enables us to consider
334 how the 'test' should evolve over the course of an eradication scheme.

335

336

337 Methods

338 We estimated the herd-level sensitivity and specificity of a spot test of young stock using the
339 frequency distribution of the number of BVD antibody-positive animals within a sample of young
340 stock from Scottish beef suckler herds. Our starting point was the modelled distribution of a mixture
341 of components for the number of positive ELISA antibody tests out of ten as published by Brülisauer
342 et al.⁸ identified and described three statistically distinct groups or classes of herds on the basis of
343 their within-herd seroprevalence levels: these groups are characterised by low, intermediate and
344 high antibody seroprevalences. Brülisauer et al. (2010)⁸ described these groups statistically thus
345 making them amenable to simulation (Figure 1).

346 We hypothesised that each group reflects an epidemiologically important class of herd with the
347 group characterised by low seroprevalences reflecting negative status herds and the group with high
348 seroprevalences reflecting positive status herds. The status of herds with intermediate
349 seroprevalences remains unclear and has several possible explanations^{8,11,12} (see Discussion above).
350 We explore here the consequences of both the extreme scenarios that this intermediate group is
351 fully negative or fully positive whilst recognising that it could be a mixture of both negative and
352 positive herds.

353 We then envisaged the relatively high herd-level prevalence which might be expected at the outset
354 of an eradication scheme and compared it with the relatively low prevalence anticipated in the latter
355 stages. We sought to demonstrate the varying rate of false negatives, false positives and predictive
356 values dependent on the prevalence as well as the screening design.

357 The simulation was carried out using the following procedure which is also illustrated in a flow
358 diagram (Figure 6).

359 *The simulated population*

We constructed a population of 2000 simulated herds (we chose 2000 because this is the approximate number of suckler herds in the sampling frame of Scottish population originally studied), which were distributed among the three classes of herds described above (i.e., herd classes characterised by low, intermediate, and high antibody seroprevalence levels within groups of young stock). The proportion of herds in each class was simulated based on published data⁸. We then simulated the true antibody seroprevalence in young stock within each herd (i.e., the overall proportion of young animals in each herd that are truly antibody positive), based on the range of seroprevalence values reported for the class of each herd. All simulation parameter values were based on published estimates, as presented in Table 3.

Testing for antibodies to BVDv

From each simulated herd, a sample of a fixed number of animals was drawn (the exact sample size varied depending on the scenario: see below for more detail). No assumption for the total number of young stock in the herd was made as this was not necessary – it was merely assumed that each herd had sufficient young stock to fulfil the desired sample. The true status (antibody-positive or antibody-negative) of each animal in the sample was determined based on a random binomial distribution defined by the overall proportion of antibody-positive animals in the herd. The test status of each animal in the sample was then determined on the basis of its true status and the (imperfect) test performance parameters (test sensitivity and specificity at the individual-animal level) drawn from the triangular distributions described in Table 3.

Herd-level status determination

We then envisaged a cut-point for the number of test-positive animals in the sample at, or above which, the sampled herd would be deemed to be positive. If the number of test positives was below that cut-point then the herd was interpreted as being negative.

Calculating herd-level sensitivity and specificity

Therefore, we had 2000 herds each of which was from one of the three classes of herd (characterised by low, intermediate or high antibody seroprevalence). The low-seroprevalence class of herd was described as negative, and the high-seroprevalence as positive. The intermediate seroprevalence group of herd was treated as either negative or positive depending on which scenario we selected. This status was, in effect, our (simulated) “true” status for the herd. For each herd we also had the number of individual test-positive animals, and therefore when compared to a chosen cut-point the herd was designated “test positive” or “test negative”. As the test is not perfect, some herds may be truly negative but test-positive and vice versa. By summing over all herds we then calculated the proportion of “true” positive herds that tested positive and similarly for negative herds to estimate the herd-level sensitivity and specificity of the screening regimen.

Herd-level specificity and sensitivity under different scenarios

Different scenarios were examined to explore the consequences of important contributing factors on the predicted herd-level specificity and sensitivity:

- Different sample sizes (the number of young stock tested);
- Different cut-points; and
- Different assumptions about the group of herds characterised by intermediate seroprevalence.

False negative, false positive rates and predictive values

The resulting simulated herd-level sensitivity and specificity estimates were used to estimate rates of false negatives and false positives and to estimate positive and negative predictive values under two different scenarios: a) high BVDv prevalence as typical of the early stages for an eradication scheme and b) low BVDv prevalence as typical of an “end-game” scenario towards the latter stages of an eradication scheme. The high BVDv herd-level prevalence was set at 60%^{8,21–23}. The low BVDv herd-

407 level prevalence scenario was hypothesised at 0.5% based on work by Løken and Nyberg (2013) ²⁴ in
408 which after 7 years of eradication the prevalence had dropped to 0.5%.

409 *Simulating uncertainty*

410 Each run of the model provided a single estimate of the herd-level sensitivity and specificity, based
411 on 2000 herds. In order to estimate the *variation* or uncertainty, we ran the model 2000 times (to
412 provide a 95% precision of $\pm 0.5\%$ on a proportion of 1%), thus giving a range of values for herd-level
413 sensitivity and specificity.

414

415 Competing interest statement

416 The authors have no competing interests as defined by Nature Research, or other interests that
417 might be perceived to influence the results and/or discussion reported in this paper.

418
419 Data availability

420 The only data used in this study were generated through random simulation as described in the
421 methods section.

422 Acknowledgements

423 The study was funded by Rural Affairs, Food and the Environment (RAFE) of the Scottish
424 Government.
425
426

427 Bibliography

- 428 1. Gunn, G. J., Saatkamp, H. W., Humphry, R. W. & Stott, A. W. Assessing economic and social
429 pressure for the control of bovine viral diarrhoea virus. *Prev. Vet. Med.* **72**, 149–162 (2005).
- 430 2. Gunn, G. J., Stott, A. W. & Humphry, R. W. Modelling and costing BVD outbreaks in beef
431 herds. *Vet. J.* **167**, 143–9 (2004).
- 432 3. Sandvik, T. Progress of control and prevention programs for bovine viral diarrhea virus in
433 Europe. *Vet. Clin. North Am. Anim. Pract.* **20**, 151–+ (2004).
- 434 4. Presi, P., Struchen, R., Knight-Jones, T., Scholl, S. & Heim, D. Bovine viral diarrhea (BVD)
435 eradication in Switzerland-Experiences of the first two years. *Prev. Vet. Med.* **99**, 112–121
436 (2011).
- 437 5. Houe, H. Bovine virus diarrhoea virus: detection of Danishdairy herds with persistently
438 infected animals bymeans of a screening test of ten young stock. *Prev. Vet. Med.* **19**, 241–248
439 (1994).
- 440 6. Houe, H. Epidemiological features and economical importanceof bovine virus diarrhoea virus
441 (BVDV) infections. *Vet. Microbiol.* **64**, 89–107 (1999).
- 442 7. Radostits, O. M., Gay, C. C., Hinchcliff, K. W. & Constable, P. D. in 1505, Coccidiosis (2007).
- 443 8. Brülisauer, F., Lewis, F. I., Ganser, A. G., McKendrick, I. J. & Gunn, G. J. The prevalence of
444 bovine viral diarrhoea virus infection in beef suckler herds in Scotland. *Vet. J.* **186**, 226–231
445 (2010).
- 446 9. The Scottish Government. The Scottish BVD Eradication Scheme. (2017). Available at:
447 [http://www.gov.scot/Topics/farmingrural/Agriculture/animal-](http://www.gov.scot/Topics/farmingrural/Agriculture/animal-welfare/Diseases/disease/bvd/eradication)
448 [welfare/Diseases/disease/bvd/eradication](http://www.gov.scot/Topics/farmingrural/Agriculture/animal-welfare/Diseases/disease/bvd/eradication). (Accessed: 17th May 2017)

- 449 10. The Scottish Government. The BVD Eradication Scheme - Phase 4 - Vets Guidance. *The BVD*
450 *Eradication Scheme - Phase 4 - Vets Guidance* (2015). Available at:
451 <http://www.gov.scot/Publications/2015/06/9489/4>.
- 452 11. Rufenacht, J., Schaller, P., Audige, L., Strasser, M. & Peterhans, E. Prevalence of cattle
453 infected with bovine viral diarrhoea virus in Switzerland. *Veterinary-Record* **147**, 413–417
454 (2000).
- 455 12. Viltrop, A., Alaots, J., Pärn, M. & Must, K. Natural changes in the spread of bovine viral
456 diarrhoea virus (BVDV) among Estonian cattle. *J. Vet. Med. Ser. B* **49**, 263–269 (2002).
- 457 13. Rothman, K. J. & Greenland, S. *Modern Epidemiology*. (Lippincott Williams & Wilkins, 1998).
- 458 14. Houe, H. & Meyling, A. Prevalence of Bovine Virus Diarrhea (Bvd) in 19 Danish Dairy Herds
459 and Estimation of Incidence of Infection in Early-Pregnancy. *Prev. Vet. Med.* **11**, 9–16 (1991).
- 460 15. Alenius, S., Lindberg, A. & Larsson, B. A national approach to the control of bovine viral
461 diarrhoea virus. in *Proceedings of the 3rd ESVV Symposium on Pestivirus infections, Lelystad*
462 (eds. Edwards, S., Paton, D. J. & Wensvoort, G.) 162–169 (CVL Weybridge (UK), 1997).
- 463 16. Lindberg, A. L. E. Regionalised eradication of bovine viral diarrhoea virus in Sweden - An
464 approach complementary to the current control scheme. in *SOCIETY FOR VETERINARY*
465 *EPIDEMIOLOGY AND PREVENTIVE MEDICINE, PROCEEDINGS* (ed. Thrusfield, MV and Goodall,
466 EA) 146–156 (1996).
- 467 17. Lindberg, A. L. E. & Alenius, S. Principles for eradication of bovine viral diarrhoea virus (BVDV)
468 infections in cattle populations. *Vet. Microbiol.* **64**, 197–222 (1999).
- 469 18. Seki, Y., Seimiya, Y. M., Yaegashi, G. & Sato, C. Identification of herds with cattle persistently
470 infected with bovine viral diarrhoea virus by virological evaluation of three calves. *J. Vet. Med.*
471 *Sci.* **68**, 255–8 (2006).

- 472 19. Booth, R. E. & Brownlie, J. Comparison of bulk milk antibody and youngstock serology screens
473 for determining herd status for Bovine Viral Diarrhoea Virus. *BMC Vet. Res.* **12**, 177 (2016).
- 474 20. SVANOVA. *SVANOVIR®BVDV-Ab Sets the standard for controlling bovine viral diarrhoea virus (*
475 *BVDV)*.
- 476 21. Humphry, R. W., Brülisauer, F., McKendrick, I. J., Nettleton, P. F. & Gunn, G. J. Prevalence of
477 antibodies to bovine viral diarrhoea virus in bulk tank milk and associated risk factors in
478 Scottish dairy herds. *Vet. Rec.* **171**, 445 (2012).
- 479 22. Sayers, R. G., Byrne, N., O'Doherty, E. & Arkins, S. Prevalence of exposure to bovine viral
480 diarrhoea virus (BVDV) and bovine herpesvirus-1 (BoHV-1) in Irish dairy herds. *Res. Vet. Sci.*
481 **100**, 21–30 (2015).
- 482 23. Meyling, a, Houe, H. & Jensen, a M. Epidemiology of bovine virus diarrhoea virus. *Rev. Sci.*
483 *Tech.* **9**, 75–93 (1990).
- 484 24. Løken, T. & Nyberg, O. Eradication of BVDV in cattle: the Norwegian project. *Vet. Rec.* **172**,
485 661 (2013).
- 486 25. Vose, D. *Risk Analysis: A Quantitative Guide*. (John Wiley & Sons Ltd, West Sussex, 2000).
- 487
- 488

489 Author contribution statement

490 Dr Humphry envisaged and implemented the method and wrote the first draft.

491 Dr Reeves provided epidemiological expertise and quality control.

492 Prof Gunn provided relevant context of eradication schemes and quality control.

493

494 Data availability statement

495 The data used in this study were all generated through simulation based on the statistical
496 distributions described in a publicly available paper⁸.

497 Tables

498 Table 1. Median (& 95% percentile) herd-level sensitivity, specificity, false negative rate amongst
 499 positive herds and false positive rate amongst negative herds based on five animals and a cut-point
 500 of two seropositive animals (as written into the Netherlands' eradication programme).

	If herds with intermediate within-herd seroprevalence are treated as positive	If herds with intermediate within-herd seroprevalence are treated as negative
Sensitivity	75% (66%, 83%)	100% (99.6%, 100%)
False negative rate amongst pos herds	25% (17%, 34%)	0% (0%, 0.4%)
Specificity	99.9% (99.4%, 100%)	90% (86%, 94%)
False positive rate amongst neg herds	0.10% (0%, 0.5%)	10% (6%, 14%)

501

502

503 Table 2. Overall probability of false negatives and positives based on a sample size of five young stock and the comparing the cut-point of two seropositive
504 animals to one seropositive animal.

		If herds with intermediate within-herd seroprevalence are treated as positive		If herds with intermediate within-herd seroprevalence are treated as negative	
	Cut-point number of positive animals	1/5	2/5	1/5	2/5
High herd-level prevalence (60% of herds)	Overall Probability of False neg	4.5% (2.4%, 7.4%)	15% (10%, 21%)	0% (0%, 0%)	0% (0%, 0.2%)
	Overall Probability of False pos	2.6% (1.3%, 3.9%)	0.06% (0%, 0.21%)	8.67% (6.46%, 10.66%)	3.92% (2.55%, 5.59%)
	Positive predictive value	95.5% (93.3%, 97.7%)	99.87% (99.5%, 100%)	87.4% (84.9%, 90.3%)	93.87% (91.47%, 95.92%)
	Negative predictive value	89.26% (83.51%, 93.98%)	72.67% (65.86%, 79.53%)	100.00% (100.00%, 100.00%)	100.00% (99.33%, 100.00%)
Low herd-level prevalence (5% of herds)	Overall Probability of False neg	0.04% (0.02%, 0.06%)	0.1% (0.09%, 0.17%)	0.00% (0%, 0%)	0.00% (0%, 0.002%)
	Overall Probability of False pos	6.5% (3.3%, 9.8%)	0.1% (0%, 0.52%)	21.57% (16.08%, 26.51%)	9.74% (6.34%, 13.90%)
	Positive predictive value	6.64% (4.47%, 12.29%)	71.25% (41.58%, 100.00%)	2.27% (1.85%, 3.02%)	4.88% (3.47%, 7.31%)

505

Negative predictive value	99.96% (99.93%, 99.98%)	99.87% (99.83%, 99.91%)	99.96% (99.94%, 99.98%)	100.00% (100.00%, 100.00%)
---------------------------	----------------------------	----------------------------	----------------------------	-------------------------------

Table 3. The parameters and their 95% credible intervals from ⁸, and consequent triangular distributions ²⁵ used to simulate the number of true positives and the number of test positives (see Supplementary Information for more detail).

Parameter	Published 95% Credible Interval	Triangular distribution (min, mode, max)
π_1 The proportion of herds characterised by low within-herd seroprevalence	(0.623, 0.742)	0.606, 0.683, 0.759
π_2 The proportion of herds characterised by intermediate within-herd seroprevalence	(0.113, 0.213)	0.099, 0.163, 0.227
π_3 The proportion of herds characterised by high within-herd seroprevalence	(0.116, 0.197)	0.104, 0.157, 0.209
μ_1 The within-herd seroprevalence for herds with low seroprevalence	(0,0)	NA
μ_2 The within-herd seroprevalence for herds with intermediate seroprevalence	(0.263, 0.385)	0.245, 0.324, 0.403
μ_3 The within-herd seroprevalence for herds with high seroprevalence	(0.919, 0.998)	0.908, 0.959, 1.000
S_e The sensitivity of the individual (animal-level) test for BVDv antibody	(0.919, 0.998)	0.908, 0.959, 1.000
S_p The specificity of the individual (animal-level) test for BVDv antibody	(0.980, 0.993)	0.978, 0.987, 0.995

511 Figure legends

512 Figure 1. A graphical presentation of the three groups of herds identified and described on the basis
513 of different levels of antibody seroprevalence in a study involving seroprevalence of ten young stock
514 from Scottish beef suckler herds ⁸


515 Figure 2. The herd-level test performance (sensitivity in black, specificity in red) where the group of
516 herds with intermediate within-herd seroprevalence is treated as either positive or negative and
517 using a sample size of either five or ten animals.

518 Figure 3. The median overall probability of false negatives with a cut-point of two positive animals
519 and if herds with intermediate within-herd seroprevalence are treated as is positive.


520 Figure 4. The median overall probability of false negatives with a cut-point of one positive animal
521 and if the herds with intermediate within-herd seroprevalence are treated as positive.

522 Figure 5. The median overall probability of false negatives as a function of the number of animals
523 tested, two different prevalence levels (60% and 0.5%) and cut-points of one and two positive
524 animals.


525 Figure 6. Flow diagram representing the process by which herd-level sensitivity and specificity (and
526 uncertainty around these) was generated using the published estimates for animal-level antibody
527 seroprevalence and test performance for each of the components identified in the source paper⁸




Sample size of 10, middle group assumed positive




Sample size of 10, middle group assumed negative




Sample size of 5, middle group assumed positive




Sample size of 5, middle group assumed negative




Middle group positive, cut-point 2



Middle group positive, cut-point 1



Middle group positive, cut-point 2



Middle group positive, cut-point 1

